Blue Trust Inc. Increases Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Blue Trust Inc. raised its position in Option Care Health, Inc. (NASDAQ:OPCH) by 16.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,703 shares of the company’s stock after purchasing an additional 681 shares during the period. Blue Trust Inc.’s holdings in Option Care Health were worth $109,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Handelsbanken Fonder AB lifted its holdings in shares of Option Care Health by 43.5% in the third quarter. Handelsbanken Fonder AB now owns 47,800 shares of the company’s stock valued at $1,496,000 after purchasing an additional 14,500 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Option Care Health by 110.6% during the 3rd quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock worth $28,000 after purchasing an additional 471 shares during the last quarter. UMB Bank n.a. lifted its stake in Option Care Health by 937.5% in the 3rd quarter. UMB Bank n.a. now owns 830 shares of the company’s stock valued at $26,000 after buying an additional 750 shares in the last quarter. Creative Planning grew its holdings in Option Care Health by 116.7% during the 3rd quarter. Creative Planning now owns 38,149 shares of the company’s stock valued at $1,194,000 after buying an additional 20,546 shares during the last quarter. Finally, Compass Wealth Management LLC increased its position in Option Care Health by 75.5% during the third quarter. Compass Wealth Management LLC now owns 193,128 shares of the company’s stock worth $6,045,000 after buying an additional 83,053 shares in the last quarter. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Barrington Research upped their price objective on Option Care Health from $32.00 to $33.00 and gave the company an “outperform” rating in a research report on Tuesday, January 14th. Bank of America upgraded Option Care Health from a “neutral” rating to a “buy” rating and boosted their price target for the company from $26.00 to $33.00 in a report on Monday, January 13th. The Goldman Sachs Group downgraded Option Care Health from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $38.00 to $27.00 in a research report on Monday, November 4th. Truist Financial dropped their price objective on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, UBS Group initiated coverage on shares of Option Care Health in a research report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Option Care Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

Option Care Health Stock Down 1.6 %

Shares of Option Care Health stock opened at $30.82 on Friday. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $34.63. The stock has a market cap of $5.24 billion, a price-to-earnings ratio of 25.90, a price-to-earnings-growth ratio of 2.19 and a beta of 1.35. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The company has a fifty day moving average price of $25.75 and a 200 day moving average price of $27.90.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.